MV-NIS or Investigator's Choice Chemotherapy in Treating Patients With Ovarian, Fallopian, or Peritoneal Cancer
Status:
Recruiting
Trial end date:
2024-03-28
Target enrollment:
Participant gender:
Summary
This randomized phase II trial studies how well oncolytic measles virus encoding thyroidal
sodium iodide symporter (MV-NIS) compared to investigator's choice chemotherapy works in
treating patients with ovarian, fallopian, or peritoneal cancer. Measles virus, which has
been changed in a certain way, may be able to kill tumor cells without damaging normal cells.